港股异动 | 加科思-B(01167)再涨超12% SHP2抑制剂联用研究数据发表于学术期刊

智通财经
May 13, 2025

智通财经APP获悉,加科思-B(01167)再涨超12%,截至发稿,涨11.26%,报4.15港元,成交额1736.32万港元。

消息面上,加科思发布宣布,其自主研发的SHP2抑制剂sitneprotafib(JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》),文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有响应的代表性患者病例。目前公司正在开展sitneprotafib与戈来雷塞联用的III期临床试验,这标志着sitneprotafib是全球首个进入III期临床试验的 SHP2抑制剂。

研究表明sitneprotafib显著增强了KRAS G12C抑制剂戈来雷塞在未接受治疗和耐药模型中的抗肿瘤活性。Sitneprotafib与MEK抑制剂联合用药可显着延缓RTK信号的再启动,并增强KRAS突变癌症模型中的肿瘤生长抑制。Sitneprotafib与奥希替尼联合用药在奥希替尼耐药的非小细胞肺癌(NSCLC)模型中表现出优异的疗效。此外,sitneprotafib通过促进抗肿瘤微环境增强了PD-1抗体的疗效。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10